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Background: CYP2C19 genotyping has been proposed for personalized antiplatelet therapy but whether it reliably identifies HPR at baseline or 
during MCT is unknown.
Methods: Aspirin treated patients (n=261; 118 on MCT and 143 clopidogrel-naive) were genotyped for the common loss- and gain- of function 
CYP2C19 *2 and *17 alleles, respectively. The ability of genotypes, diplotypes and metabolizer status to predict HPR was evaluated.
Results: Thirty-two percent and 36% were *2 and *17 carriers, respectively; *2 or *17 did not affect baseline platelet reactivity. During MCT, 
aggregation was higher in *2 carriers and lower in *17 carriers (p< 0.05). The highest platelet aggregation was observed in patients homozygous 
for the CYP2C19*2 allele while the lowest aggregation was observed in patients homozygous for the *17 allele. The sensitivity of *2 to identify HPR 
was 55%; specificity was 72%; positive predictive value 41%; and negative predictive value was 82%. The sensitivity of *17 to identify HPR was 45%; 
specificity was 81%; positive predictive value was 87% and negative predictive value was 34% for. Platelet reactivity stratification was improved by 
diplotype and metabolizer status analysis.
Conclusions: Both common gain- and loss-of function CYP2C19 alleles affect platelet reactivity in patients on MCT. Future larger prospective 
studies for personalized P2Y12 therapy may be enhanced by combining information on *2 and *17 allele status.
